SNS Financial Group LLC Has $2.97 Million Position in AbbVie Inc. $ABBV

SNS Financial Group LLC raised its stake in AbbVie Inc. (NYSE:ABBV) by 79.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 13,005 shares of the company’s stock after buying an additional 5,767 shares during the quarter. SNS Financial Group LLC’s holdings in AbbVie were worth $2,971,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Oppenheimer Asset Management Inc. increased its position in shares of AbbVie by 0.9% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 187,578 shares of the company’s stock worth $42,860,000 after purchasing an additional 1,634 shares during the period. Secured Retirement Advisors LLC raised its stake in AbbVie by 3.8% in the fourth quarter. Secured Retirement Advisors LLC now owns 1,685 shares of the company’s stock valued at $385,000 after purchasing an additional 62 shares in the last quarter. Sigma Planning Corp raised its stake in AbbVie by 0.7% in the fourth quarter. Sigma Planning Corp now owns 59,304 shares of the company’s stock valued at $13,554,000 after purchasing an additional 383 shares in the last quarter. Belleair Asset Management LLC acquired a new position in AbbVie in the fourth quarter valued at about $247,000. Finally, Safe Harbor Family Capital LLC acquired a new position in AbbVie in the fourth quarter valued at about $269,000. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. Berenberg Bank set a $275.00 price target on AbbVie in a research note on Tuesday, January 20th. Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Piper Sandler dropped their price target on AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Royal Bank Of Canada initiated coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.90.

AbbVie Trading Up 3.8%

Shares of NYSE ABBV opened at $211.66 on Friday. The company has a market cap of $374.26 billion, a price-to-earnings ratio of 104.27, a PEG ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 12 month low of $176.57 and a 12 month high of $244.81. The stock has a 50-day moving average price of $214.55 and a two-hundred day moving average price of $221.60.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.46 earnings per share. On average, sell-side analysts predict that AbbVie Inc. will post 14.13 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s payout ratio is presently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and guidance lift — AbbVie reported Q1 revenue of $15.00B and adjusted EPS of $2.65, beat consensus on sales and raised its 2026 adjusted EPS range to $14.08–$14.28. The beat and guide raise highlight Skyrizi/Rinvoq strength and drove the initial rally. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Immunology drivers — Management and coverage note that Skyrizi and Rinvoq produced the bulk of immunology gains (Skyrizi ~$4.48B, Rinvoq ~$2.12B in the quarter), helping offset Humira’s decline and underpinning the company’s raised 2026 outlook. AbbVie hikes 2026 outlook
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms bumped ratings/targets after the quarter: Bank of America upgraded ABBV to Buy and lifted its PT to $234; Morgan Stanley and Canaccord also raised targets. These upgrades add buying interest and momentum. Bank of America Upgrades AbbVie
• Neutral Sentiment: Rinvoq label expansion filing — AbbVie has filed for an FDA label expansion of Rinvoq in alopecia areata, which, if approved, would broaden the drug’s market and is a potential medium‑term revenue tailwind. ABBV Seeks FDA Nod for Rinvoq
• Neutral Sentiment: Skyrizi competitive defense — AbbVie outlined strategies to defend Skyrizi against a new J&J psoriasis entrant (Icotyde); that competitive positioning matters for long‑term share but is not an immediate financial swing. AbbVie outlines Skyrizi defense
• Neutral Sentiment: Corporate PR / innovation outreach — AbbVie awarded the RIME Therapeutics Biotech Innovators prize in Quebec, reinforcing R&D partnerships and local innovation efforts (long‑term strategic benefit). AbbVie and adMare Announce RIME Therapeutics Award
• Negative Sentiment: Pipeline pruning — AbbVie said it would discontinue a cancer candidate, a near‑term negative for pipeline optionality that could concern investors focused on long‑term oncology upside. AbbVie tops Q1, discontinues cancer candidate
• Negative Sentiment: Analyst estimate trimming & insider selling — Some shops (Erste) trimmed FY estimates slightly and public filings show recent insider sales; both are modest headwinds that can amplify short‑term volatility. (internal/market data sources)

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.